Tolmar Holding Limited

Tolmar Holding Limited focuses on developing innovative long-acting injectable therapies for urology, oncology, and endocrinology, aiming to enhance patient adherence and improve health outcomes. Tolmar Holding Limited was founded in 2007 and specializes in the development of long-acting injectable therapies. The company operates with a focus on addressing unmet medical needs in specific therapeutic areas such as urology, oncology, and endocrinology. It is headquartered in Fort Collins, Colorado, USA.

The CEO, Anil D'souza, has a solid background in the pharmaceutical industry, contributing to the company's growth and strategic direction. Tolmar specializes in the development and delivery of long-acting injectable therapies, primarily within the fields of urology, oncology, and endocrinology. Their core product offerings aim to address unmet medical needs, enhancing patient outcomes through innovative treatment solutions. Notable products include ELIGARD, used for prostate cancer management, and FENSOLVI, targeted at treating Central Precocious Puberty.

These therapies are designed to improve patient adherence and provide sustained therapeutic effects over extended periods, thereby reducing dosing frequency compared to conventional treatments. Tolmar's products are distributed across more than 89 countries, serving a diverse client base that includes healthcare providers, hospitals, and patients seeking effective long-term management of their conditions. Tolmar's revenue stream is generated primarily through the sale of its long-acting injectables to healthcare providers and institutions, which may include hospitals and specialty clinics. Transactions typically occur through a B2B model, where Tolmar engages directly with medical facilities and distributors to supply its products.

The pricing structure is based on volume purchases and negotiated contracts, reflecting the specific healthcare needs of clients. Products such as ELIGARD and FENSOLVI are central to this revenue model, as they address critical treatment protocols in their respective therapeutic areas. Additionally, Tolmar holds partnerships with various stakeholders in the healthcare sector, further enhancing their market reach and revenue potential.